GlaxoSmithKline PLC (LSE:GSK) said it appointed Tony Wood as chief scientific officer designate to replace current CSO Hal Barron.
Wood will take over from Barron on 1 August 2022 and assume full accountability for Research and Development (R&D), the pharmaceutical company said in a statement.
Barron has been appointed as chief executive officer of the new US biotech company Altos Labs from 1 August. He will remain on GSK's board and become a non-executive director, with additional responsibilities to support R&D.
Wood joined GSK from Pfizer in 2017 as senior vice president, medicinal science and technology, and is responsible for all science and technology platforms supporting the discovery, clinical development and delivery of new medicines across GSK.
Commenting on the new appointment, GSK CEO Emma Walmsley said: “Altogether, these changes provide us with a clear pathway for continued momentum in R&D to deliver our new ambitions for growth and scale impact for patients."